Today the U.S. Food and Drug Administration (FDA) approved a new use for enzalutamide (Xtandi) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC). Enzalutamide was previously approved only for patients with metastatic CRPC. Prior to this past February – when the FDA also approved apalutamide (Erleada) for non-metastatic CRPC – there were no FDA-approved treatments for these men. Read More
The Mike Slive Foundation endeavors to become a global leader in the fight to eradicate prostate cancer through public awareness and research funding in memory of Mike Slive, a transformative leader whose vision and direction revolutionized the business of collegiate sports.
The Mike Slive Foundation for Prostate Cancer Research was founded in Birmingham, Alabama, by attorney Ed Meyerson and former SEC and Conference USA Commissioner Mike Slive. Composed of local business, medical and political leaders, the Foundation’s mission is to save lives by funding cutting-edge research and by raising awareness of prostate cancer. The Mike Slive Foundation is a new weapon in the fight against prostate cancer. Follow us on Twitter, Facebook and Instagram @MikeSliveFdn.
Director of PR & Social Media